3.54
-0.45 (-11.28%)
| Previous Close | 3.99 |
| Open | 3.94 |
| Volume | 669,324 |
| Avg. Volume (3M) | 162,414 |
| Market Cap | 356,124,000 |
| Price / Earnings (Forward) | 11.24 |
| Price / Sales | 7.82 |
| Price / Book | 3.04 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -184.04% |
| Operating Margin (TTM) | -1,956.57% |
| Diluted EPS (TTM) | -0.650 |
| Quarterly Revenue Growth (YOY) | -92.30% |
| Total Debt/Equity (MRQ) | 5.46% |
| Current Ratio (MRQ) | 1.53 |
| Operating Cash Flow (TTM) | 46.00 M |
| Levered Free Cash Flow (TTM) | 57.57 M |
| Return on Assets (TTM) | -17.07% |
| Return on Equity (TTM) | -43.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | AC Immune SA | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.13 |
|
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 38.01% |
| % Held by Institutions | 26.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Handelsbanken Fonder Ab | 30 Jun 2025 | 105,000 |
| Eversept Partners, Lp | 30 Jun 2025 | 100,752 |
| 52 Weeks Range | ||
| Median | 8.00 (125.99%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 08 Sep 2025 | 8.00 (125.99%) | Buy | 2.20 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Sep 2025 | Announcement | Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine |
| 25 Sep 2025 | Announcement | Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine |
| 04 Sep 2025 | Announcement | AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway |
| 04 Sep 2025 | Announcement | AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |